MILANO ( – Envent has started the coverage on Kolinpharma with an outperform recommendation and a target price of 8.54 euros. “From minimal revenues of 0.1 million in 2014, their growth has been regular and impressive, reaching 4.1 million in 2017, with a Cagr of 202% – analysts write – The company was able to to break even in 2016 and now we expect financial results in line with industry standards over the next three years”. The estimates of Envent on Kolinpharma are now 7.1 million in revenues this year, with 1.7 million ebitda and 0.5 million net profit, while for 2019 the assets are 9.5 million in turnover, 2.6 of ebitda and 1.2 of net profits.